Brought to you by 
Elixir licenses rights to BMS's growth hormone stimulant
19 May 2009
Executive Summary
Seeking to become a fully integrated biopharmaceutical company, Elixir, which develops drugs for diseases related to aging, has licensed exclusive worldwide development and commercialization rights to Bristol-Myers Squibb's ghrelin agonist BMS-604992 (later called, EX1314, it stimulates appetite, gastric motility, and the release of growth hormone). and five related compounds to treat metabolic disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com